Please use this identifier to cite or link to this item:
Title: Irreversible electroporation (IRE): a narrative review of the development of IRE from the laboratory to a prostate cancer treatment.
Austin Authors: Blazevski, Alexandar;Scheltema, Matthijs J;Amin, Amer;Thompson, James;Lawrentschuk, Nathan;Stricker, Phillip D
Affiliation: St. Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia
Garvan Institute of Medical Research and Kinghorn Cancer Centre, Darlinghurst, NSW, Australia
St. Vincent's Clinical School, University of New South Wales, Sydney, Australia
Department of Urology, Amsterdam UMC, Amsterdam, The Netherlands
EJ Whitten Prostate Cancer Research Centre at Epworth Healthcare, Melbourne, Australia
Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia
Department of Surgery, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia
Issue Date: Mar-2020 2019-12-05
Publication information: BJU International 2020; 125(3): 369-378
Abstract: Whilst whole gland radical treatment is highly effective for prostate cancer control, it confers significant impact on quality of life (QOL) and is unnecessary 'over-treatment' in many men with screening detected prostate cancer. Improvements in prostate biopsy and imaging have led to the increased interest in partial gland ablation to reduce treatment-related morbidity. Several energies for focal ablation have been trialled. Irreversible electroporation (IRE) is a novel technology which ablates tissue by delivering direct current between electrodes. This narrative review aims to document the history of electroporation including its scientific basis, early data from pre-clinical animal studies and contemporary clinical outcomes from the use of IRE in prostate cancer. A literature search using MEDLINE, Embase, PubMed and Google Scholar was undertaken to identify historical perspectives and current clinical data relating to IRE for prostate cancer. The history of electroporation and its implementation as a prostate cancer treatment was following the basic scientific principles, in-vitro data then animal studies and now short- to medium-term clinical cohorts in humans. The results of IRE on more than 283 patients have been published in several papers, with preserved rates of (pad-free) continence in 91-100% of men and preserved erectile function in 79-100% of men. In-field recurrence rates range from 0% to 33%. The current state of evidence for IRE in treatment of primary and salvage prostate cancer is considered IDEAL stage 2B. IRE is a new focal ablative technology for the treatment of localised prostate cancer in carefully selected men. Published cohorts reported encouraging short-term oncological and functional outcomes, however longer-term data is needed to validate this treatment before it can be recommended for widespread clinical use.
DOI: 10.1111/bju.14951
ORCID: 0000-0002-7063-5509
PubMed URL: 31725935
Type: Journal Article
Subjects: Electroporation
focal therapy
organ-sparing treatments
prostate neoplasms
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Dec 2, 2022

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.